5th November 2018
Coventry, UK, 5th November 2018 / Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has successfully compl
3rd October 2018
Coventry, UK, 3rd October 2018 / Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has been awarded a Medic
David Davies
7th March 2018
Medherant Ltd, a leader in next-generation transdermal drug delivery, is pleased to announce the appointment of a new senior executive, David Davies, as Head of Development. This appointment marks a significant expansion of the Company’s management team to support the business as it moves into clinical development of its ibuprofen TEPI Patch®.
11th December 2017
Medherant, a leader in next-generation transdermal drug delivery, has raised £3.8 million in its latest funding round. The fundraising was led by majority shareholder Mercia Technologies PLC, with the balance coming from other existing shareholders as well as new private investors. This latest investment will support the company as it progresses its ibuprofen TEPI Patch® into clinical development in early 2018.
17th November 2017
Medherant is delighted to announce they have been awarded the ‘Excellence in Science & Technology Award’ at the Coventry Telegraph Business Awards last night. These Awards are a celebration of companies in Coventry and Warwickshire which have achieved success for themselves, their staff and their customers.
27th September 2017
Coventry, UK, 27th September 2017 / Medherant, a leader in next-generation transdermal drug delivery, has signed an agreement with a Japanese transdermal patc
26th June 2017
Medherant Ltd, a University of Warwick spin-out company developing a next-generation transdermal drug delivery patch technology, is pleased to announce the appointment of two new senior executives, Sally Waterman and Angus Hone. These appointments mark a significant expansion of the Company’s management team to support the business as it moves into clinical development and commercialisation of its ibuprofen TEPI Patch®.
12th June 2017
Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, has been chosen as one of 40 companies shortlisted for the Royal Society of Chemistry (RSC) Emerging Technologies Competition 2017.
6th June 2017
Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, is pleased to announce the appointment of Sheryl Caswell as Head of Clinical Development.
8th May 2017
Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, has appointed Laboratoires Plasto Santé to manufacture its first drug delivery patches.

Pages